يعرض 1 - 4 نتائج من 4 نتيجة بحث عن '"Petra Hoffknecht"', وقت الاستعلام: 0.62s تنقيح النتائج
  1. 1
    Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)

    المؤلفون: Felix Steger, Anke Schlenska-Lange, Marlitt Horn, M. Faehling, Jürgen Alt, Stephan Eisenmann, Wolfgang M. Brückl, Daniel C. Christoph, Petra Hoffknecht, Christian Schumann, Petros Christopoulos, Philipp Schütt

    المصدر: Lung Cancer. 150:114-122

    مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Durvalumab, Population, Locally advanced, non-small cell lung cancer (NSCLC), 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Internal medicine, medicine, Humans, education, Adverse effect, education.field_of_study, business.industry, Antibodies, Monoclonal, Chemoradiotherapy, Definitive chemoradiotherapy, medicine.disease, 030104 developmental biology, 030220 oncology & carcinogenesis, Expanded access, business

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef66eca88e3a561eb53d42359b372b12Test
    https://doi.org/10.1016/j.lungcan.2020.10.006Test


    أضف إلى المفضلة
  2. 2
    Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy

    المؤلفون: Linda Diehl, Balázs Jóri, Petra Hoffknecht, H. Ramdani, Len Kaller, Frank Griesinger, S. Schatz, Lukas C. Heukamp, Bettina Kah, Christian Grohé, Markus Tiemann, Markus Falk, J. Roeper

    المصدر: Cancers
    Volume 13
    Issue 12
    Cancers, Vol 13, Iss 2861, p 2861 (2021)

    مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_treatment, Article, 03 medical and health sciences, 0302 clinical medicine, Second line, Tki resistance, Medicine, Osimertinib, Liquid biopsy, Lung cancer, osimertinib resistance, RC254-282, liquid biopsy, business.industry, Hybrid capture, Disease progression, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, routine diagnostics, respiratory tract diseases, lung cancer, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Cancer research, business, Adjuvant

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b652b9684fd65dc190c6bb81d2a1f57eTest


    أضف إلى المفضلة
  3. 3
    KRAS G12C-mutated advanced non-small cell lung cancer : A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

    المؤلفون: Stephanie Dille, A. Fleitz, Jacqueline Rauh, Lukas C. Heukamp, Marlen Sandberg, Tobias Dechow, Albrecht Stenzinger, Frank Griesinger, Mike Thomas, Konrad Kokowski, Matthias Groschek, Wilko Weichert, Wolfgang Schütte, Wilfried Eberhardt, Jürgen Alt, Reinhard Büttner, Stefan Zacharias, Martin Sebastian, Martina Jänicke, Eyck von der Heyde, Thomas Wehler, A. Hipper, Petra Hoffknecht, Martin Metzenmacher

    مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Medizin, medicine.disease_cause, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Carcinoma, Non-Small-Cell Lung, Germany, Medicine, Humans, Prospective Studies, Registries, Lung cancer, neoplasms, business.industry, Standard treatment, medicine.disease, ddc, respiratory tract diseases, 030104 developmental biology, 030220 oncology & carcinogenesis, Trk receptor, Cohort, Mutation, Population study, Observational study, KRAS, business, Cohort study

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99033094ddf7a1abf8a1507bdf20369eTest
    https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85100908806Test


    أضف إلى المفضلة
  4. 4
    Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer

    المؤلفون: Lukas C. Heukamp, Balázs Jóri, S. Schatz, Eva-Maria Willing, Matthias Kröger, Harry J.M. Groen, Linda Diehl, Stefanie Schmidt, Markus Falk, Hayat Oum El Kheir Ramdani, Frank Griesinger, Markus Tiemann, C. Wesseler, Roopika Menon, Petra Hoffknecht

    المساهمون: Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS)

    المصدر: Cancers, 12(6):1685, 1-14. MDPI AG
    Cancers
    Volume 12
    Issue 6
    Cancers, Vol 12, Iss 1685, p 1685 (2020)

    مصطلحات موضوعية: 0301 basic medicine, Oncology, PD-L1, Cancer Research, medicine.medical_specialty, tumor mutational burden, BLOCKADE, NEOANTIGENS, PHASE-1, medicine.disease_cause, lcsh:RC254-282, Article, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, IMMUNOHISTOCHEMISTRY, Lung cancer, immuno-oncology, Mutation, biology, business.industry, driver mutation, Routine laboratory, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, routine diagnostics, OPEN-LABEL, EFFICACY, Immune checkpoint, respiratory tract diseases, lung cancer, 1ST-LINE TREATMENT, 030104 developmental biology, 030220 oncology & carcinogenesis, biology.protein, NIVOLUMAB PLUS IPILIMUMAB, Biomarker (medicine), Non small cell, Antibody, SENSITIVITY, business

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c8ac4497f7a0a8ca98d267c72164bc1Test
    https://research.rug.nl/en/publications/3f08a1fc-fe7c-4f77-9a0f-80bf8ce9b9c8Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث